Skip to content
Screener

AdaptHealth AHCO Q2 2026 earnings

Reported August 4, 2026 · Before market open

Revenue$740.3MMiss by $106.5M
EPS$0.06Miss by $0.11
Revenue estimate$846.8M
EPS estimate$0.17
In the second quarter, we delivered 15.9% organic growth, with record volume gains across the business. Also, in July we signed a definitive agreement to divest our Diabetes Health business, the most significant step yet in our multi-year effort to focus AdaptHealth on our core Sleep Health, Respiratory Health, and supporting Wellness-at-Home businesses. Our West Coast capitated partnership reached full scale in the quarter, and the complexity of that transition has impacted our margins. Together with an unexpected price increase from one of our manufacturers, this has led us to lower our full-year outlook. We are moving quickly to address the cost pressures introduced by our rapid growth, and we believe these actions will make us a stronger, more efficient company.
Suzanne Foster

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$725.9M
EPS estimate-$0.05

Valuation & ratios

Valuation

as of 09/16/26
See full
Market cap$776.44M-37.8%
Enterprise value$2.73B-12.8%
P/S0.2×-0.2×

Versus estimates

FAQ

When did AdaptHealth report Q2 2026 earnings?
AdaptHealth (AHCO) reported Q2 2026 earnings on August 4, 2026 before market open.
What were AdaptHealth's Q2 2026 revenue and EPS?
AdaptHealth reported revenue of $740.3M and eps of $0.06 for Q2 2026.
Did AdaptHealth beat estimates in Q2 2026?
Revenue missed the consensus estimate of $846.8M by $106.5M. EPS missed the consensus estimate of $0.17 by $0.11.
How did AdaptHealth's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 7.5% from $800.4M a year earlier and eps grew 500.0% from $0.01.
Where can I find AdaptHealth's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-052149) and the 10-Q periodic report (0001628280-26-052646) directly on SEC EDGAR. The filing index links above go to sec.gov.